Investigational drug · Phase 3
JP-1366
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for H. Pylori Eradication Therapy, Non-erosive Gastroesophageal Reflux Disease, Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
15
Any phase or sponsor naming "JP-1366"
First trial start
2024
Oct 22, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JP-1366", any sponsor or status.
Conditions studied
As listed on its trial records.
- H. Pylori Eradication Therapy
- Non-erosive Gastroesophageal Reflux Disease
- Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
- Peptic Ulcer
Approved drugs for the same conditions: Stomach and esophageal cancer · Acid reflux (GERD) · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "JP-1366" as an intervention, largest first.
- Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive SubjectsPivotal-lookingNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07875933 · 414 participants (planned) · Start Nov 1, 2026 · Primary completion Sep 6, 2028
Drug: JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg; Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg · For: H. Pylori Eradication Therapy
- Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive EsophagitisPivotal-lookingNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07732075 · 384 participants (planned) · Start Aug 1, 2026 · Primary completion Oct 30, 2028
Drug: JP-1366 10 mg; Lansoprazole 15mg · For: Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)
- Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic UlcersPivotal-lookingRecruiting
Onconic Therapeutics Inc.Industry
NCT06439563 · 364 participants (planned) · Start Oct 22, 2024 · Primary completion Aug 2027
Drug: JP-1366 10 mg; Lanston Capsule 15 mg and 2 more · For: Peptic Ulcer
Sites: Seoul, South Korea
- A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux EsophagitisPivotal-lookingRecruiting
Livzon Pharmaceutical Group Inc.Industry
NCT06850480 · 356 participants (planned) · Start Dec 5, 2024 · Primary completion Apr 15, 2025
Drug: JP-1366 simulation tablets; Esomeprazole Magnesium (Nexium) simulation tablets · For: Reflux Esophagitis (RE)
Sites: Beijing, China
- Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric UlcerPivotal-lookingCompleted
Onconic Therapeutics Inc.Industry
NCT05448001 · 329 participants · Start Sep 19, 2022 · Primary completion Jul 10, 2024
Drug: JP-1366 20mg; Lansoprazole 30mg · For: Gastric Ulcer
Sites: Seoul, South Korea
- Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux DiseasePivotal-lookingNot yet recruiting
Onconic Therapeutics Inc.Industry
NCT07160790 · 321 participants (planned) · Start Sep 2, 2025 · Primary completion Jun 30, 2026
Drug: JP-1366 + placebo; Placebo + Placebo · For: Non-erosive Gastroesophageal Reflux Disease
- JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive EsophagitisPivotal-lookingCompleted
Onconic Therapeutics Inc.Industry
NCT05443984 · 300 participants · Start Jan 17, 2022 · Primary completion Jan 5, 2023
Drug: JP-1366 20mg; Esomeprazole 40mg · For: Erosive Esophagitis
Sites: Seoul, South Korea
- Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux DiseasePivotal-lookingCompleted
Onconic Therapeutics Inc.Industry
NCT04282954 · 188 participants · Start Nov 15, 2019 · Primary completion Oct 20, 2020
Drug: JP-1366; JP-1366 placebo and 2 more · For: GERD
Sites: Seoul, South Korea
- Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male SubjectsPivotal-lookingCompleted
Jeil Pharmaceutical Co., Ltd.Industry
NCT03383042 · 115 participants · Start Dec 22, 2017 · Primary completion Nov 23, 2018
Drug: Cohort 1 (JP-1366 A mg); Cohort 2 (JP-1366 B mg) and 7 more · For: Anti-Ulcer Agents
Sites: Seoul, South Korea
Onconic Therapeutics Inc.Industry
NCT07265466 · 96 participants (planned) · Start Nov 17, 2025 · Primary completion Mar 30, 2026
Drug: JP-1366 and clopidogrel; JP-1366 and aspirin and 2 more · For: Drug Drug Interaction (DDI)
Sites: Seongnam-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
- Effect of Food on the Pharmacokinetics, Pharmacodynamics, and Safety of Zastaprazan, a Potassium-Competitive Acid Blocker, in Healthy Participants.
Lee H, Yoon SK, Jung SM, et al. · Clin Transl Sci 2026
- Randomized, Double-Blind, Active-Controlled, Parallel, Phase 3 Clinical Trial for Evaluating the Efficacy and Safety of Zastaprazan in Patients with Gastric Ulcers.
Park KS, Kim HS, Oh JH, et al. · Gut Liver 2026
- CYP3A-Mediated Metabolism of Zastaprazan in Humans and Associated Drug-Drug Interactions.
Cao KJ, Fu L, Sun YC, et al. · Pharmaceutics 2026
- Pharmacokinetics, mass balance, and metabolism of the novel potassium-competitive acid blocker JP-1366 in healthy Chinese adults following a single oral dose of [14C]JP-1366.
Liu X, Deng D, Meng J, et al. · Front Pharmacol 2025
- Evaluation of drug-drug interaction potentials between JP-1366 and celecoxib using physiologically based pharmacokinetic modeling.
Choi SC, Kim J, Lim HS · Transl Clin Pharmacol 2025
- Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers.
Yang E, Hwang I, Ji SC, et al. · CPT Pharmacometrics Syst Pharmacol 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.